- Evolus ( NASDAQ: EOLS ) said Wednesday it concluded certain royalty payments related to the 2021 settlement of litigation claims between the company, Medytox and Allergan - which is now part of AbbVie ( ABBV ).
- EOLS continues to expect its adj. gross profit margin for the quarter ending Dec. 31 to grow 68-71%.
- "The conclusion of these royalty payments represents the beginning of a significantly improved financial profile reflecting stronger profit margins, which keeps us on a path to reaching profitability," said EOLS CEO David Moatazedi.
For further details see:
Evolus concludes certain royalty payments related to settlement of IP rights dispute